Search

The article discusses a clinical trial, NCT06664008, focusing on the effects of probiotic and zinc supplementation in patients with Gastroesophageal Reflux Disease (GERD). The study aims to evaluate the impact of probiotics and zinc on GERD symptoms, inflammation, and oxidative stress. It involves four study groups receiving different treatments, with assessments conducted before and after a 4-week period. The research aims to provide insights into the potential benefits of probiotics and zinc in managing GERD symptoms and their anti-inflammatory and antioxidant effects. [Extracted from the article]

A study conducted at Vall d'Hebron University Hospital in Barcelona, Spain, focused on patients with systemic sclerosis who had gastroesophageal reflux disease resistant to proton-pump inhibitors (PPI). The research found that gastrointestinal dysmotility, characterized by abnormal gastric emptying and small bowel dilation, was significantly associated with PPI-refractory oesophagitis in these patients. The study suggests that gastric and small intestinal motor dysfunction may play a crucial role in the development of PPI-refractory oesophagitis in individuals with systemic sclerosis. [Extracted from the article]

A study conducted at the Mayo Clinic in Rochester, Minnesota examined the impact of proton pump inhibitors (PPIs) on the effectiveness of fluoropyrimidine-based chemotherapy in pancreatic adenocarcinoma (PDAC) patients. The study found that the use of PPIs did not significantly influence major pathologic response (mPR) rates or overall survival (OS) in patients receiving neoadjuvant chemotherapy. The researchers concluded that further analysis of all patients, not just those who underwent resection, is necessary. This information may be useful for individuals researching pancreatic cancer treatments. [Extracted from the article]

A recent report from the Veterans Affairs Medical Center in Syracuse, New York, discusses the increasing diagnosis of gastroesophageal reflux disease (GERD) in adults and its treatment with proton pump inhibitors (PPIs). The report highlights that many PPIs are not being used according to evidence-based guidelines, and emphasizes the importance of healthcare providers reviewing updated guidelines for the treatment of GERD and deprescribing PPIs. The report concludes by suggesting a comprehensive deprescribing PPI protocol. This research has been peer-reviewed and is available in The Journal for Nurse Practitioners. [Extracted from the article]

A recent study conducted at the Hospital Aleman of Buenos Aires in Argentina explored the outcomes of endoscopic antireflux mucosectomy (ARMS) as a treatment for gastroesophageal reflux disease (GERD). The study included a systematic review and meta-analysis of 22 studies involving 654 patients. The results showed that ARMS was associated with improved patient satisfaction, reduced use of proton pump inhibitors, and enhanced quality of life for GERD patients. However, the study also noted a morbidity rate of 27%, indicating a need for refinements in the technique to decrease adverse events. [Extracted from the article]

A recent study conducted in Barcelona, Spain, explored the factors associated with proton pump inhibitor (PPI)-refractory esophagitis in patients with systemic sclerosis. The researchers found that patients with PPI-refractory esophagitis were more likely to have diffuse systemic sclerosis and gastrointestinal dysmotility, characterized by abnormal gastric emptying and/or small bowel dilated loops. However, absent esophageal contractility or a hypotensive lower esophageal sphincter were not significantly associated with PPI-refractory esophagitis. These findings suggest that gastric and small intestinal motor dysfunction may play a role in the development of PPI-refractory esophagitis in patients with systemic sclerosis. [Extracted from the article]

A recent study conducted in Greenville, South Carolina, examined the effects of prolonged use of proton-pump inhibitors (PPIs) on renal dysfunction and bone fragility. The study found that patients who used PPIs for longer than the recommended trial period of 8 weeks had higher rates of osteoporosis/osteopenia and chronic kidney disease (CKD) compared to those who did not use PPIs. The research suggests that long-term PPI use may be associated with an increased risk of these conditions, but further studies are needed to confirm these findings. [Extracted from the article]

A recent report discusses the use of proton pump inhibitors (PPIs) in the treatment of eosinophilic esophagitis (EoE) in children. The study aimed to determine if the expression of certain genes in the esophageal mucosa could predict the responsiveness to PPI therapy. The researchers found that children with PPI-nonresponsive EoE had higher baseline gene expression of mast cell, cytokine, proton pump, and eosinophil genes compared to those with PPI-responsive EoE. This suggests that PPIs may be involved in an inflammatory cascade that leads to eosinophil recruitment. [Extracted from the article]

The article examines the use of proton pump inhibitors (PPIs) in liver cirrhosis patients, highlighting issues with overprescription. Topics discussed include the misalignment with clinical guidelines, the common inappropriate indications for PPI use, and the need for increased adherence to prescribing practices.

The article from Hospital Universitario Austral discusses recent advances in treating gastroesophageal reflux disease (GERD) through endoscopic antireflux mucosectomy (ARMS). Topics include the effectiveness of ARMS in improving patient satisfaction and quality of life, the reduction in proton pump inhibitor use, and the associated morbidity rates and procedural complications.

A recent study conducted by researchers at the University Medical Center of the Johannes Gutenberg-University in Mainz, Germany, has found that the use of proton pump inhibitors (PPIs) is associated with an increased risk of fractures in patients with chronic kidney disease (CKD). The study, which used a population-based observational case-control design, analyzed data from the IQVIATM Disease Analyzer database and found that PPI use was linked to a higher risk of fractures in patients with CKD. The researchers suggest that deprescribing PPIs in patients without a specific indication for treatment could be a modifiable risk factor to reduce fracture risk in this high-risk group. [Extracted from the article]

A study investigated the link between proton-pump inhibitor (PPI) therapy and Clostridioides difficile (C. difficile) infections. The study found that changes in gastrointestinal pH, rather than direct effects on the gut microbiome, were responsible for the increased risk of C. difficile infection associated with PPI therapy. The findings suggest that reducing infection risks in PPI therapy may be possible by addressing alterations in gastrointestinal pH. However, it is important to note that this study has not yet undergone peer review. [Extracted from the article]

A recent study conducted by researchers at Rutgers University - The State University of New Jersey has found a link between the use of proton pump inhibitors (PPIs) and an increased risk of chronic kidney disease (CKD). PPIs are commonly prescribed medications, but their use has been associated with the development of CKD and cardiovascular events. The study, which included twelve studies with over 700,000 participants, revealed that PPI use was associated with a statistically significant increased risk of incident CKD compared to non-users. The researchers recommend cautious and judicious use of long-term PPIs and suggest further large prospective studies to validate these findings. [Extracted from the article]

A recent study conducted by the Karolinska Institute in Sweden aimed to evaluate the risk of colorectal adenocarcinoma (CRA) associated with long-term use of proton pump inhibitors (PPIs). The study utilized Swedish national registries to identify adults who had 180 days of cumulative PPI use between July 2005 and December 2012. The results showed that maintenance PPI users exhibited a slightly elevated risk of CRA compared to the general population, particularly among individuals aged 18-39 and 40-49. However, there was no significant difference in the risk of CRA between maintenance PPI users and maintenance histamine-2 receptor antagonist (H2RA) users. Further research with a longer observation time is needed to fully understand the association between PPI use and colorectal cancer risk. [Extracted from the article]

A recent study conducted by researchers at Prince of Songkla University in Thailand compared the efficacy of Vonoprazan (VPZ) and intravenous proton pump inhibitors (PPIs) in preventing re-bleeding in high-risk peptic ulcer patients. The study used a randomized, double-blind, controlled design and assessed re-bleeding rates, blood transfusions, hospitalization length, and ulcer healing rate. The results showed comparable efficacy between VPZ and PPIs in preventing recurrent bleeding events after successful endoscopic hemostasis. This study provides valuable insights into the treatment options for high-risk peptic ulcer patients. [Extracted from the article]

A new report published by researchers from the Norwegian University of Science and Technology (NTNU) examines the effects of proton pump inhibitors (PPIs) on the gastrointestinal microbiota. PPIs are commonly used medications that reduce stomach acid production. The study found that PPI use can lead to changes in the diversity and richness of the gastrointestinal microbiota, with an increase in bacteria typically found in the oral microbiota. The most consistent taxonomic alterations were observed in the Streptococcaceae and Veillonellaceae families. This research raises concerns about the potential adverse effects of PPI use on the microbiota and its implications for disease risk and progression. [Extracted from the article]

A recent study conducted at CHA Gangnam Medical Center compared the effectiveness and safety of two procedures, antireflux mucosectomy (ARMS) and antireflux mucosal ablation (ARMA), for the treatment of gastroesophageal reflux disease (GERD). The study included 274 patients, with 96 undergoing ARMA and 178 undergoing ARMS. The primary outcome measured was subjective symptom improvement based on GERD questionnaire scores. The study found that both procedures showed improvements in GERD symptoms, but ARMS demonstrated better outcomes in terms of both subjective and objective indicators, such as reflux esophagitis and proton pump inhibitor withdrawal rates. [Extracted from the article]

A new report from the Karolinska Institute in Stockholm, Sweden discusses research findings on chronic kidney disease (CKD) and its potential association with the use of Proton Pump Inhibitors (PPIs). The study aimed to assess the relationship between PPI use and CKD progression by analyzing estimated glomerular filtration rate (eGFR) trajectories using a process mining approach. The analysis revealed that PPI users had more complex and rapidly declining eGFR trajectories compared to users of H2 blockers (H2Bs), with a 75% increased risk of transitioning to more severe stages of CKD. These findings suggest that PPI use may be associated with an increased risk of CKD progression. [Extracted from the article]

A recent study conducted by researchers at Landspitali University Hospital in Reykjavik, Iceland, has shed light on the potential risks associated with long-term use of proton pump inhibitors (PPIs). PPIs are commonly used to treat conditions such as gastroesophageal reflux disease (GERD) and peptic ulcers. The study found that one of the adverse effects of long-term PPI use is rebound acid hypersecretion (RAHS), which occurs when gastric acid production increases after discontinuing PPI therapy. This can lead to gastrointestinal symptoms and may mistakenly be attributed to the recurrence of underlying conditions, resulting in unnecessary continuation of PPI therapy. The mechanisms of RAHS are well established, but further research is needed to fully understand its clinical implications and risk factors. [Extracted from the article]

A recent survey conducted by researchers at the University of Florence explored the perspectives and unmet needs of systemic sclerosis (SSc) patients who use proton pump inhibitors (PPIs) to treat gastrointestinal (GI) symptoms. The survey, which included 301 respondents from 14 countries, found that while the majority of patients reported improvement in GI symptoms with PPIs, not all patients responded to the therapy and many remained on long-term treatment. Concerns about the long-term safety of PPIs were also raised. The survey highlighted the importance of upper GI symptoms in SSc patients and the need for improved patient education about PPIs. Further research is needed to optimize the therapeutic strategy for PPI use in SSc. [Extracted from the article]

A study published in the journal Neurology Clinical Practice suggests that people who take acid-reducing drugs, such as proton pump inhibitors and antacids, may have a higher risk of experiencing migraines and severe headaches. However, the study only shows an association and does not prove that these drugs cause migraines. Acid reflux, which can lead to gastroesophageal reflux disease (GERD), is a condition where stomach acid flows into the esophagus. The researchers recommend further investigation into the potential implications of acid-reducing drugs and their association with migraines. It is important for individuals taking these medications to consult with their doctors about whether they should continue. [Extracted from the article]

A recent study from the General Hospital de Tomelloso explores the use of proton-pump inhibitors (PPIs) as a first-line treatment for eosinophilic esophagitis (EoE). However, only about half of EoE patients respond to double-dose PPI treatment, and efforts to identify responders using clinical features and biomarkers have been unsuccessful. The study suggests that PPI pharmacogenetics, specifically variations in CYP2C19 and STAT6 genes, may be a promising approach to predict PPI response in EoE patients. The research provides an overview of PPI treatment in EoE and discusses the role of pharmacogenetics in predicting PPI effectiveness. [Extracted from the article]

A recent study conducted at Princess Royal University Hospital in Madrid, Spain, explored the effectiveness of proton pump inhibitors (PPIs) in treating eosinophilic esophagitis (EoE). The researchers aimed to identify genetic biomarkers that could predict the response to PPIs and their association with disease features. The study found that patients treated with omeprazole had a higher reduction in eosinophil count compared to other PPIs. Additionally, certain genetic variations, such as STAT6 rs12368672 and rs167769, were found to potentially impact EoE status and PPI response. Further research is needed to fully understand the clinical relevance of these genetic variants. [Extracted from the article]

A recent study conducted by researchers at Shanghai Jiao Tong University explores the association between proton pump inhibitors (PPIs) and the risk of hepatic encephalopathy (HE) in patients undergoing transjugular intrahepatic portosystemic shunt (TIPS) placement. HE is a major complication of acute liver failure, cirrhosis, and TIPS placement, with symptoms ranging from mild cognitive deficits to coma. PPIs are commonly used in clinical practice for the treatment of HE, but there is inconsistent evidence regarding their risk relationship with post-TIPS HE. This study aims to provide a systematic evaluation of this relationship through a meta-analysis of relevant information from various databases. The results of the study will be published in a peer-reviewed journal. [Extracted from the article]

A recent study conducted at Brigham and Women's Hospital in Boston, Massachusetts, examined the optimal proton pump inhibitor (PPI) regimen for eosinophilic esophagitis (EoE). The study found that a twice-daily PPI regimen resulted in higher histologic response rates compared to a once-daily regimen, regardless of the total daily dose. Approximately 42.3% of patients achieved a histologic response to PPI, with higher rates observed in the twice-daily moderate and high dose groups. The findings suggest that a twice-daily PPI regimen may be more effective in treating EoE. [Extracted from the article]

A recent study conducted at two Canadian universities aimed to understand the perceptions of primary and specialty care trainees regarding the long-term prescribing of proton pump inhibitors (PPIs). The study found that there is a lack of formal education on prescribing PPIs long-term, with only 42% of trainees having received such education. However, 93% of trainees believed they would benefit from this type of teaching and 98% stated they would follow related guidelines. The study also revealed that inappropriate PPI prescribing and deprescribing is common among trainees, highlighting the need for educational programs on PPI usage. [Extracted from the article]

A systematic review and meta-analysis conducted by researchers from Tabriz University of Medical Sciences in Iran examined the association between proton pump inhibitor (PPI) use and the occurrence of spontaneous bacterial peritonitis (SBP) or hepatic encephalopathy (HE) in cirrhotic patients. The study found that the use of PPIs was associated with a higher risk of SBP and HE in cirrhotic patients. However, the quality of the included studies was moderate, and further high-quality studies with larger sample sizes are needed to confirm these findings. This research has been peer-reviewed. [Extracted from the article]

A study conducted by researchers at Chungbuk National University College of Medicine in South Korea examined the effects of a proton-pump inhibitor (PPI) on postnasal drip (PND) symptoms in patients with laryngopharyngeal reflux (LPR). LPR is a condition where stomach acid refluxes into the upper airways, and PND is a common consequence of LPR. The study found that PPI treatment for 8 weeks was effective in improving PND symptoms in patients with LPR. This research provides valuable insights into the management of acid reflux disease and its associated symptoms. [Extracted from the article]

A recent study conducted at the First Affiliated Hospital of Sun Yat-Sen University in Guangzhou, China compared the efficacy and safety of potassium competitive acid blockers (P-CABs) and proton pump inhibitors (PPIs) in healing grade C/D esophagitis. The researchers performed a systematic literature search and identified 24 eligible studies. The results showed that vonoprazan, a P-CAB, had considerable efficacy in healing grade C/D esophagitis compared to PPIs, with moderate short-term and long-term safety. This research provides valuable information for clinical decision-making in the treatment of severe gastroesophageal reflux disease. [Extracted from the article]

A recent mini-review article from Semnan University of Medical Sciences in Iran discusses the potential risk of renal failure associated with the use of proton pump inhibitors (PPIs), which are commonly used to treat acid-related disorders. The article highlights that prolonged or high-dose use of PPIs, as well as pre-existing kidney disease or other risk factors, may increase the risk of renal failure. The mechanism behind this association is not fully understood but may involve changes in renal blood flow and tubular function. The researchers suggest that clinicians should be aware of these potential risks and consider alternative treatment options for patients with renal impairment or other risk factors. Regular monitoring of kidney function may also be necessary for patients on long-term PPI therapy. [Extracted from the article]

A study conducted at Brigham and Women's Hospital in Boston, Massachusetts, has found that there is a correlation between food and environmental allergies and the response to proton pump inhibitor (PPI) therapy in patients with eosinophilic esophagitis (EoE). The study included adults with newly diagnosed EoE who underwent allergen testing and PPI therapy. The results showed that patients with positive food allergen testing were more likely to be nonresponders to PPI therapy. The study suggests that formal allergen testing may be useful in selecting appropriate therapy for EoE. [Extracted from the article]

A recent study conducted by the Department of Gastroenterology examined the characteristics of proton pump inhibitor (PPI)-resistant severe reflux esophagitis (RE) in elderly and non-elderly patients. The study found that stenosis and bleeding complications were more common in the elderly group. The efficacy of vonoprazan (VPZ) in treating RE was also assessed and found to be similar in both groups. However, it was noted that VPZ may not be sufficient for non-elderly patients with scleroderma. The study highlights the differences in hernias and collagen disease prevalence between the two groups. [Extracted from the article]

A report from Long Island University discusses the relationship between proton pump inhibitors (PPIs) and kidney disease. The researchers highlight concerns about the inappropriate usage of PPIs and its potential consequences, including worsening kidney function. They suggest that patients with kidney disease who are taking long-term PPI therapy should be closely monitored for signs and symptoms of kidney disease. The researchers also recommend reassessing and deprescribing PPIs when necessary. This research has been peer-reviewed and can be found in the Nephrology Nursing Journal. [Extracted from the article]

A recent study conducted by researchers at the University of Belgrade in Serbia explored the use of the Eosinophilic Esophagitis Histology Scoring System (EoEHSS) in predicting the response to proton pump inhibitor (PPI) therapy in children with eosinophilic esophagitis (EoE). EoE is an immune-mediated esophageal disease that is on the rise, and PPIs are the first-line treatment. However, a significant number of patients do not respond to PPIs. The study found that the EoEHSS can be a valuable tool in predicting therapy response, particularly when biopsies are taken from each esophageal segment, with the middle segment showing a higher EoEHSS grade score in non-responders. This emphasizes the need for personalized therapeutic approaches in managing EoE. [Extracted from the article]

A report from Weill Cornell Medical College discusses the perception of side effects of proton pump inhibitors (PPIs) among members of the American Broncho-esophagological Association (ABEA). The study found that the majority of respondents were concerned about PPI side effects, particularly osteoporosis, renal dysfunction, and dementia. As a result, many respondents had modified their prescription patterns, with some avoiding PPIs altogether and preferring H2-receptor blockers for the management of gastroesophageal reflux disease (GERD) and laryngopharyngeal reflux (LPR). The research highlights the awareness and changes in reflux management practices among ABEA members due to concerns about PPI side effects. [Extracted from the article]

A study conducted by researchers at Guangzhou University of Chinese Medicine explored the relationship between the use of proton pump inhibitors (PPIs) and various types of digestive system tumors. The study utilized a 2-sample Mendelian randomization approach and analyzed data from the UK Biobank and the Finland Biobank. The results showed a significant causal relationship between the use of omeprazole, a commonly used PPI, and pancreatic malignancies. However, no causal relationship was found with other types of digestive system tumors. The study concluded that PPIs may be a protective factor for pancreatic malignancies. [Extracted from the article]

A recent report discusses the findings of a study on colon cancer and the use of proton pump inhibitors (PPIs). The study, conducted in Taiwan, aimed to explore the effect of PPIs on the prognosis of colorectal cancer patients. The researchers found that long-term usage of PPIs was associated with an increased risk of death in patients with colorectal cancer, particularly at higher cumulative doses. However, PPI usage was also found to reduce the risk of recurrence. These findings suggest that the dose-response effect of PPIs on colorectal cancer prognosis requires further exploration. [Extracted from the article]

A recent study conducted by researchers at the Medical University of Bialystok in Poland has identified ATP12A, a proton pump, as a potential therapeutic target for the treatment of cystic fibrosis and other respiratory diseases. The ATP12A protein is responsible for the secretion of protons in exchange for potassium ions in various epithelial tissues, including the airways. Increased expression and activity of ATP12A, combined with the loss of other balancing activities, can lead to excessive acidification of the airway surface liquid and mucus dysfunction, contributing to the pathogenesis of cystic fibrosis and other chronic inflammatory respiratory disorders. The study highlights the need for further research and development of therapeutic strategies aimed at inhibiting ATP12A. [Extracted from the article]

Keywords: Chronic Kidney Disease; Epidemiology; Health and Medicine; Kidney Diseases and Conditions; Membrane Proteins; Proton Pumps; Risk and Prevention EN Chronic Kidney Disease Epidemiology Health and Medicine Kidney Diseases and Conditions Membrane Proteins Proton Pumps Risk and Prevention 486 486 1 10/16/23 20231016 NES 231016 2023 OCT 16 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- New study results on chronic kidney disease have been published. Keywords for this news article include: Federal University of Sao Joao del-Rei, Epidemiology, Proton Pumps, Membrane Proteins, Health and Medicine, Risk and Prevention, Chronic Kidney Disease, Kidney Diseases and Conditions. [Extracted from the article]

Keywords: Membrane Proteins; Proton Pumps; Risk and Prevention EN Membrane Proteins Proton Pumps Risk and Prevention 456 456 1 09/25/23 20230926 NES 230926 2023 SEP 25 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Data detailed on proton pumps have been presented. According to news reporting originating from Penn State College of Medicine by NewsRx correspondents, research stated, "Proton pump inhibitors (PPIs) are the most efficacious and common medications for gastric acid suppression.". [Extracted from the article]

Compared with other treatments, PPI maintenance therapy for more than 6 months was associated with an increased risk of ECL cell hyperplasia (OR 3.01; 95% CI 1.29 to 7.04; p = 0.01). According to news reporting originating from Inner Mongolia, People's Republic of China, by NewsRx correspondents, research stated, "Long-term maintenance therapy with proton pump inhibitors (PPIs) is a common treatment strategy for acid-related gastrointestinal diseases. Keywords: Cancer; Clinical Research; Clinical Trials and Studies; Gastric Cancer; Gastroenterology; Health and Medicine; Hyperplasia; Membrane Proteins; Oncology; Proton Pumps; Risk and Prevention; Therapy EN Cancer Clinical Research Clinical Trials and Studies Gastric Cancer Gastroenterology Health and Medicine Hyperplasia Membrane Proteins Oncology Proton Pumps Risk and Prevention Therapy 982 982 1 09/11/23 20230911 NES 230911 2023 SEP 12 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Current study results on gastric cancer have been published. [Extracted from the article]

Acid Reflux, Acid Reflux Disease, Deglutition Disorders, Digestive System Diseases and Conditions, Esophageal Diseases and Conditions, Esophageal Motility Disorders, Gastroenterology, Gastroesophageal Reflux, Gastrointestinal Diseases and Conditions, Health and Medicine, Membrane Proteins, Proton Pumps Keywords: Acid Reflux; Acid Reflux Disease; Deglutition Disorders; Digestive System Diseases and Conditions; Esophageal Diseases and Conditions; Esophageal Motility Disorders; Gastroenterology; Gastroesophageal Reflux; Gastrointestinal Diseases and Conditions; Health and Medicine; Membrane Proteins; Proton Pumps EN Acid Reflux Acid Reflux Disease Deglutition Disorders Digestive System Diseases and Conditions Esophageal Diseases and Conditions Esophageal Motility Disorders Gastroenterology Gastroesophageal Reflux Gastrointestinal Diseases and Conditions Health and Medicine Membrane Proteins Proton Pumps 516 516 1 09/04/23 20230905 NES 230905 2023 SEP 4 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Fresh data on acid reflux disease are presented in a new report. [Extracted from the article]

Keywords: Blood Cells; Digestive System Diseases and Conditions; Eosinophilic Esophagitis; Eosinophils; Esophageal Diseases and Conditions; Esophagitis; Gastroenteritis; Gastroenterology; Gastrointestinal Diseases and Conditions; Genetics; Granulocytes; Health and Medicine; Hemic and Immune Systems; Immunology; Membrane Proteins; Proton Pumps EN Blood Cells Digestive System Diseases and Conditions Eosinophilic Esophagitis Eosinophils Esophageal Diseases and Conditions Esophagitis Gastroenteritis Gastroenterology Gastrointestinal Diseases and Conditions Genetics Granulocytes Health and Medicine Hemic and Immune Systems Immunology Membrane Proteins Proton Pumps 756 756 1 08/28/23 20230901 NES 230901 2023 AUG 28 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Investigators discuss new findings in eosinophilic esophagitis. Blood Cells, Digestive System Diseases and Conditions, Eosinophilic Esophagitis, Eosinophils, Esophageal Diseases and Conditions, Esophagitis, Gastroenteritis, Gastroenterology, Gastrointestinal Diseases and Conditions, Genetics, Granulocytes, Health and Medicine, Hemic and Immune Systems, Immunology, Membrane Proteins, Proton Pumps. [Extracted from the article]

Keywords: Acid Reflux; Acid Reflux Disease; Deglutition Disorders; Digestive System Diseases and Conditions; Drugs and Therapies; Esophageal Diseases and Conditions; Esophageal Motility Disorders; Gastroesophageal Reflux; Gastrointestinal Diseases and Conditions; Health and Medicine; Membrane Proteins; Mucosectomy; Proton Pumps; Surgery; Therapy EN Acid Reflux Acid Reflux Disease Deglutition Disorders Digestive System Diseases and Conditions Drugs and Therapies Esophageal Diseases and Conditions Esophageal Motility Disorders Gastroesophageal Reflux Gastrointestinal Diseases and Conditions Health and Medicine Membrane Proteins Mucosectomy Proton Pumps Surgery Therapy 1783 1783 1 08/21/23 20230821 NES 230821 2023 AUG 25 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Researchers detail new data in acid reflux disease. Acid Reflux, Acid Reflux Disease, Deglutition Disorders, Digestive System Diseases and Conditions, Drugs and Therapies, Esophageal Diseases and Conditions, Esophageal Motility Disorders, Gastroesophageal Reflux, Gastrointestinal Diseases and Conditions, Health and Medicine, Membrane Proteins, Mucosectomy, Proton Pumps, Surgery, Therapy. [Extracted from the article]

Keywords: Digestive System Diseases and Conditions; Drugs and Therapies; Enzyme Inhibitors; Gastroenterology; Gastrointestinal Bleeding; Health and Medicine; Membrane Proteins; Proton Pump Inhibitors; Proton Pumps; Therapy EN Digestive System Diseases and Conditions Drugs and Therapies Enzyme Inhibitors Gastroenterology Gastrointestinal Bleeding Health and Medicine Membrane Proteins Proton Pump Inhibitors Proton Pumps Therapy 1766 1766 1 08/07/23 20230807 NES 230807 2023 AUG 11 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Research findings on gastrointestinal bleeding are discussed in a new report. Digestive System Diseases and Conditions, Drugs and Therapies, Enzyme Inhibitors, Gastroenterology, Gastrointestinal Bleeding, Health and Medicine, Membrane Proteins, Proton Pump Inhibitors, Proton Pumps, Therapy. [Extracted from the article]

Keywords: Dialysis; Health and Medicine; Hemodialysis; Membrane Proteins; Proton Pumps EN Dialysis Health and Medicine Hemodialysis Membrane Proteins Proton Pumps 501 501 1 08/07/23 20230807 NES 230807 2023 AUG 7 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Researchers detail new data in hemodialysis. Dialysis, Health and Medicine, Hemodialysis, Membrane Proteins, Proton Pumps. [Extracted from the article]

Proton pump inhibitors (PPIs) are not only widely used in patients with CKD but also represent a known risk factor for infection in the general population." Keywords: Kasugai; Japan; Asia; Chronic Kidney Disease; Dialysis; Drugs and Therapies; Enzyme Inhibitors; Health and Medicine; Hemodialysis; Kidney Diseases and Conditions; Membrane Proteins; Proton Pump Inhibitors; Proton Pumps; Risk and Prevention; Therapy EN Kasugai Japan Asia Chronic Kidney Disease Dialysis Drugs and Therapies Enzyme Inhibitors Health and Medicine Hemodialysis Kidney Diseases and Conditions Membrane Proteins Proton Pump Inhibitors Proton Pumps Risk and Prevention Therapy 1625 1625 1 07/17/23 20230717 NES 230717 2023 JUL 21 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Current study results on Kidney Diseases and Conditions - Chronic Kidney Disease have been published. [Extracted from the article]

Drugs and Therapies, Enzyme Inhibitors, Gastroenterology, Health and Medicine, Membrane Proteins, Proton Pump Inhibitors, Proton Pumps Keywords: Drugs and Therapies; Enzyme Inhibitors; Gastroenterology; Health and Medicine; Membrane Proteins; Proton Pump Inhibitors; Proton Pumps EN Drugs and Therapies Enzyme Inhibitors Gastroenterology Health and Medicine Membrane Proteins Proton Pump Inhibitors Proton Pumps 1358 1358 1 07/17/23 20230717 NES 230717 2023 JUL 21 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Data detailed on proton pump inhibitors have been presented. [Extracted from the article]

Keywords for this news article include: St. Louis, Missouri, United States, North and Central America, Gastroenterology, Health and Medicine, Membrane Proteins, Pancreatoduodenectomy, Proton Pumps, Surgery, Washington University. Keywords: St. Louis; State:Missouri; United States; North and Central America; Gastroenterology; Health and Medicine; Membrane Proteins; Pancreatoduodenectomy; Proton Pumps; Surgery EN St. Louis State:Missouri United States North and Central America Gastroenterology Health and Medicine Membrane Proteins Pancreatoduodenectomy Proton Pumps Surgery 654 654 1 07/17/23 20230717 NES 230717 2023 JUL 17 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Current study results on Surgery - Pancreatoduodenectomy have been published. [Extracted from the article]

Keywords: Hyderabad; India; Asia; Acid Reflux; Acid Reflux Disease; Deglutition Disorders; Digestive System Diseases and Conditions; Esophageal Diseases and Conditions; Esophageal Motility Disorders; Gastroesophageal Reflux; Gastrointestinal Diseases and Conditions; Health and Medicine; Membrane Proteins; Proton Pumps EN Hyderabad India Asia Acid Reflux Acid Reflux Disease Deglutition Disorders Digestive System Diseases and Conditions Esophageal Diseases and Conditions Esophageal Motility Disorders Gastroesophageal Reflux Gastrointestinal Diseases and Conditions Health and Medicine Membrane Proteins Proton Pumps 376 376 1 06/26/23 20230626 NES 230626 2023 JUN 26 (NewsRx) -- By a News Reporter-Staff News Editor at Gastroenterology Week -- Investigators discuss new findings in Digestive System Diseases and Conditions - Acid Reflux Disease. Hyderabad, India, Asia, Acid Reflux, Acid Reflux Disease, Deglutition Disorders, Digestive System Diseases and Conditions, Esophageal Diseases and Conditions, Esophageal Motility Disorders, Gastroesophageal Reflux, Gastrointestinal Diseases and Conditions, Health and Medicine, Membrane Proteins, Proton Pumps. [Extracted from the article]